Navigation Links
Merz, Inc. Announces Cynthia Schwalm as Vice President, Neurology
Date:9/17/2012

GREENSBORO, N.C., Sept. 17, 2012 /PRNewswire/ -- Merz, Inc. (U.S. affiliate of Merz Pharma Group) today announced the appointment of Cynthia Schwalm has as vice president, neurology effective immediately. Schwalm will be responsible for the Merz's growing neurology business unit in the U.S., which includes the recently acquired product CUVPOSA®.

"Cynthia brings national as well as international experience, in developing and commercializing pharmaceutical products. We are extremely pleased to have her join the Merz team and are confident she will make immediate and important contributions to steer the future growth of our neurology business and the company as a whole," said Bill Humphries, president & CEO of Merz, Inc.

Humphries noted that he will name his entire North American Leadership Team within the next few months as Merz, Inc. and its U.S. affiliates continue to undergo integration in preparation for accelerated growth opportunities across all business units.

Prior to joining Merz, Schwalm was the Senior Advisor to the Chief Executive Officer at Chimerix, Inc. She has held various international commercial leadership and general management positions with Optimer, Eisai, Amgen, and Johnson & Johnson. Schwalm brings with her 30 years of experience in the pharmaceutical and healthcare industry, with commercialization experience in movement disorders and neurology including pain management, Alzheimer's disease, and epilepsy including Lennox Gaustaut syndrome.

Schwalm obtained her Bachelor of Science in Nursing from the University of Delaware in Newark, DE. She also earned her Executive Master of Business Administration from the Wharton School of Busin
'/>"/>

SOURCE Merz, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Merz, Inc. Announces Promotion of Katrina Church to Vice President, Chief Compliance Officer
2. Heska Corporation Announces Amendment To Its Odd-Lot Tender Offer
3. Onconome Announces Results Of Blood Test For Colorectal Cancer; Further Trials Underway
4. Valeant Pharmaceuticals Announces Management Change
5. Neuralstem Announces Proposed Public Offering
6. PPCE Announces Strategic Partnership With ECLINSO AG
7. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
10. Henry Schein Announces New $500 Million Credit Facility
11. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
(Date:7/30/2015)... OSAKA, Japan , July 30, 2015 /PRNewswire/ ... completion of the study to fulfill the post-marketing ... from the Pan European Multi-Database Bladder Cancer ... multi-database retrospective matched cohort study, conducted in four ... (pioglitazone HCI) with up to 10 years of ...
(Date:7/30/2015)... 2015   Sentrian , the Remote Patient ... recently received confirmation from the Food & Drug ... solution meets the definition of a "medical device" ... Discretion." The designation identifies medical ... regulatory requirements at this time" and clears the ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
... Dehaier Medical Systems Ltd. (Nasdaq: DHRM) ("Dehaier" or ... marketing and sale of medical devices and homecare medical ... quarter ended March 31, 2012. (Logo: ... Financial and Operating Highlights (percentage comparisons are year over ...
...  Accuray Incorporated (Nasdaq: ARAY ), the premier ... third quarter of fiscal 2012 that ended March 31, ... Accuray,s consolidated results including the results for TomoTherapy which ... are provided to enhance understanding of Accuray,s ongoing core ...
Cached Medicine Technology:Dehaier Medical Announces 2012 First Quarter Financial Results 2Dehaier Medical Announces 2012 First Quarter Financial Results 3Dehaier Medical Announces 2012 First Quarter Financial Results 4Dehaier Medical Announces 2012 First Quarter Financial Results 5Dehaier Medical Announces 2012 First Quarter Financial Results 6Dehaier Medical Announces 2012 First Quarter Financial Results 7Dehaier Medical Announces 2012 First Quarter Financial Results 8Accuray Announces Results for Third Quarter Fiscal 2012 2Accuray Announces Results for Third Quarter Fiscal 2012 3Accuray Announces Results for Third Quarter Fiscal 2012 4Accuray Announces Results for Third Quarter Fiscal 2012 5Accuray Announces Results for Third Quarter Fiscal 2012 6Accuray Announces Results for Third Quarter Fiscal 2012 7Accuray Announces Results for Third Quarter Fiscal 2012 8Accuray Announces Results for Third Quarter Fiscal 2012 9Accuray Announces Results for Third Quarter Fiscal 2012 10Accuray Announces Results for Third Quarter Fiscal 2012 11Accuray Announces Results for Third Quarter Fiscal 2012 12Accuray Announces Results for Third Quarter Fiscal 2012 13Accuray Announces Results for Third Quarter Fiscal 2012 14
(Date:7/30/2015)... & Caicos Islands, BWI (PRWEB) , ... July 31, 2015 , ... The Venetian on ... for fall, 2015. Guests who stay at the Venetian will save 40% on their ... The fall months are always quiet in the Turks & Caicos, providing a chance to ...
(Date:7/30/2015)... ... 30, 2015 , ... The Clinical Data Interchange Standards Consortium ... announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis ... . These three Therapeutic Area (TA) standards were developed per the CDISC global, ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will ... site. As discussed in a June 8, 2015 article published by Nasdaq , ... have been caused by its computer-driven cars, which such industry players as Tesla CEO ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2
... patients would bear the brunt of a Government proposal to ... ,This plan would very likely push up the ... to pay for their medication facing a greater financial burden, ... it ensures that Australians are able to access the ...
... avian influenza since 2005, state media said Friday. ... a 29-year-old man has been infected with the deadly H5N1 ... to Vietnam News Agency. ,The man, from Vinh ... from high fever and breathing difficulties on May 10. He ...
... improve global public health, Weill Cornell Medical College students ... the World Health Organization's (WHO) list of essential ... to choose which high-priority drugs should be supplied to ... chapter of Universities Allied for Essential Medicines (UAEM) answered ...
... that they have identified a gene that needs to be ... ,The gene detected by the researchers ... of the well-known breast cancer gene BRCA1. ,The ... of the University of Pennsylvania and the Dana-Farber Cancer Institute, ...
... that appetite-regulating peptides leptin and ghrelin influence alcohol cravings ... powerful urge to drink, is an important contributor to ... Otto Lesch of the University of Vienna has divided ... that refers to people with heavy alcohol withdrawals who ...
... has opened one of the few clinics in the ... Down Syndrome. Because of improvements in diagnosis, treatment ... patients are now routinely living into adulthood, and have ... of the population. ,Childrens hospitals, pediatricians and our ...
Cached Medicine News:Health News:Medical College Students Help Change Global Health Policy 2Health News:Scientists Identify New Breast Cancer Gene 2Health News:Appetite-regulating Peptides Influence Alcohol Cravings 2Health News:Adult Down Syndrome Clinic Opened at UAB 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: